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Despite considerable efforts and quite early initiated anti-tuber-
culosis (TB) actions, Lithuania still remains one of the European 
Union (EU) countries with the highest tuberculosis rates, espe-
cially multidrug-resistant (MDR) TB. According to the European 
Centre for Disease Prevention and Control, in 2016, 58 994 cases 
of TB were reported in 30 EU/European Economic Area (EEA) 
countries. MDR TB was reported for 3.7% of 36 071 cases with 
drug susceptibility testing results and continues to be highest in 
the three Baltic countries - Estonia, Latvia and Lithuania.
In this article we present the Lithuanian anti-TB action history 
review and comparison with other countries in this area of action. 
Literature review was performed by using documents available 
in the Martynas Mazvydas Library’s resource, articles of foreign 
authors and archival materials.
According to archaeological studies, tuberculosis was common 
in Europe including Lithuania in the Middle Ages. Tuberculosis 
reporting started in Lithuania in 1926. The first tuberculosis san-
atorium in Lithuania was opened in 1891. Patients were treated 
with sun bathing procedures, fresh air and sunlight. Later the 
treatment included pneumothorax, toracocaustic, toracoplastic, 
treatment with gold products and other procedures. Lithuania 
introduced directly observed treatment, short course therapy 
(DOTS) in 1999, and since 2007 it has been working in accord-
ance with the requirements of this strategy.
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The fight against tuberculosis
It is believed that mycobacterium appeared more than 
150 million years ago and claimed more human lives 
that any other well-known pathogen [1]. Three million 
years ago early hominids in the East Africa might be 
infected with M. tuberculosis (MT) ancestors  [2]. Pre-
sumably, approximately 35-15 thousand years ago M. 
tuberculosis complex bacteria, including Mycobacteri-
um africanum, Mycobacterium canettii, Mycobacterium 
bovis had a common ancestor in Africa [2-4]. In Egypt 
tuberculosis was documented more than five thousand 
years ago. Skeletal abnormalities typical to tuberculosis, 
including Pott’s deformation, were found in Egyptian 
mummies and clearly portrayed by the early Egyptian 
art [5-8]. Early humans began to migrate out of Africa 
more than 1.7 million years ago. These migrants were 
largely replaced by the subsequent wave of people over 
the last 35 to 89 thousand years [9]. Assumably, the mi-
grants came with diseases, including tuberculosis. The 
first written documents describing TB, dating back to 
3300 and 2300 years ago, were found in India and in 
China respectively [7, 10].
Archaeological evidence showed that tuberculosis 
was common in the Middle Ages in Europe. Clovis of 
France, who included the touch of persons with scrofula 
in his coronation ceremony in 496, may have been the 
first European monarch to touch scrofulous persons, and 
for many generations his descendants claimed to have 
inherited his healing power. The illness was known in 
England and France as “king’s evil”, and it was widely 
believed that persons affected could heal after a royal 
touch [11, 12]. Archaeological findings proved existence 
of tuberculosis also in Lithuania in 14-15th and 18-19th 
century. In Leipalingis the excavation with spine abnor-
malities typical to tuberculosis was found (Fig. 1) [13]. 
Within the framework of the Lithuanian Mummy Pro-
ject, seven spontaneously mummified human bodies 
from a church crypt in Vilnius, dating from the 18th-19th 
century, were CT-scanned to assess the presence of tu-
berculosis or other lung diseases. Authors encountered 
pulmonary lesions suggestive of cases of pulmonary 
tuberculosis. In addition, one case might have been af-
fected by extra-pulmonary tuberculosis [14].
The history of tuberculosis was radically changed on 
24th of March 1882 when Robert Koch gave his pres-
entation about the etiology of tuberculosis in the Berlin 
Physiologists Society and declared postulates. In 1905 
he was awarded the Nobel Prize for tuberculosis etiol-
ogy interpretation. His Nobel lecture included a number 
of effective anti-TB recommendations relevant today: 
tuberculosis patient isolation, continued treatment in 
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specialized dispensaries, information of the population, 
especially the patients’ next of kin, their education, the 
need to register all TB cases because the statistical infor-
mation was necessary [15, 16].
A copy of the honorary member’s diploma awarded by 
the Vilnius (Lithuania) Medical Society to R. Koch on 
the 12th of December 1895 was found in the Vilnius Uni-
versity Library Manuscript Department Archive Fund. 
R. Koch’s letter of thanks for this award was also stored. 
The Fund maintains documents attesting correspondence 
of R. Koch with the Vilnius Medical Society Presidents 
who used his findings in combating tuberculosis [17].
More vigorous action in the fight against tuberculosis 
was launched in Lithuania in 1911. At that time a meet-
ing was convened in Kaunas where it was decided to 
establish a division of the recently created All-Russian 
League for Fighting Against Tuberculosis. In 1914 As-
sociation activities were terminated due to the war. In 
1921, in the first Congress of Lithuanian doctors it was 
decided to set up Society for Combating Tuberculosis 
(SCT)  [18]. Doctor Kazys Grinius initiated the estab-
lishment of SCT on 31 July 1924. He was elected as a 
Chairman and one of the editors of the publication “The 
fight against phthisis”. SCT purpose was to combat the 
spread of tuberculosis. SCT disseminated information 
on tuberculosis, studied the causes of the disease, treat-
ments and outcomes, founded and maintained sanato-
riums, hospitals, shelters, boarding houses, children’s 
summer camps, tuberculosis departments in hospitals, 
clinics, emergency points, took care of the children’s 
protection against tuberculosis, supported the poor pa-
tients and their families, cooperated with Lithuanian and 
foreign organizations. SCT in its activities followed the 
practice of other countries [19, 20]. In 1927 the SCT had 
11 sections embracing about one thousand members. In 
1934 it has expanded its activities and had 12 operating 
sections, 11 dispensaries, 1 sanatorium, 7 quartz lamps, 
2 X-ray apparatus and 1.5 thousand members [21].
In Lithuania mortality rate from tuberculosis was count-
ed by the City Board based on the death certificates pre-
sented by physicians. The calculations were not accurate, 
about 20 percent of people were buried without a death 
certificate. In 1926 the journal “The fight against phthi-
sis” mentioned that the fight against tuberculosis was 
just beginning, while the mortality rate from tuberculo-
sis was around 30 cases per 10000 population in Lithu-
ania [20], in 1923 in Estonia - 25.6 cases per 10000 pop-
ulation, in 1925 – 22.9 cases per 10000 population [22]. 
In 1925 3903 people died from tuberculosis in Latvia, in 
1926 - 3798 [23]. In 1920 the mortality rate from tuber-
culosis in Sweden reached 16.2 cases per 10000 popula-
tion in the Netherlands - 14.9 cases per 10000 popula-
tion, in England - 11.3 cases per 10000 population, in 
Denmark 10.6 cases per 10000 population [20]. In 1934 
around 6 000 people died of tuberculosis in Lithuania, 
about 5 percent of the population had tuberculosis [18]. 
German and Swiss models to fight tuberculosis were 
considered successful. Germans maintained 17 765 beds 
ex gratis and nearly 3 thousand dispensaries and similar 
institutions [24]. 
In Lithuania health services were hardly available to the 
patients with “milder” tuberculosis (about 60 thousand). 
Lithuanian villages were very poor. Most of the cases 
remained undiagnosed. The suggested actions against 
tuberculosis included establishment of the outpatient 
departments-dispensaries, free special trainings on tu-
berculosis lead by doctors, school curricula about health 
and hygiene [20]. At the time tuberculosis was called a 
“disease of uneducated people”, so SCT particularly fo-
cused on education: “the school must educate not only 
cultured but also healthy citizens” [24].
Tuberculin skin test (TST)
In 1890 R. Koch presented the work about substance 
isolation from the tuberculosis bacteria in the tenth In-
ternational Medical Conference in Berlin. R. Koch has 
named this substance tuberculin, it was intended to treat 
tuberculosis. Soon, this substance was rejected as inef-
fective. R. Koch injected tuberculin himself and noticed 
an unset of fever up to 39.6°C and unusual tremor. Af-
ter this experiment R. Koch offered to use tuberculin for 
disease diagnostic. The Danish veterinarians continued 
with further tuberculin tests  [25, 26]. TST is used to 
diagnose persons who have been sensitized by Myco-
bacterium tuberculosis, a condition referred to as latent 
tuberculosis infection. Clemens von Pirquet was the first 
Fig. 1. Human spine deformed by tuberculosis, Leipalingis, Lithu-
ania, 14-15th century.
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scientist who mentioned and introduced the concept of 
latent tuberculosis in his works. In 1907 von Pirquet cre-
ated the tuberculin skin test, which was used to identify 
the persons who previously had been in contact with TB. 
It made clear that the majority of people infected with 
tuberculosis were asymptomatic and might suffer from 
active tuberculosis in the future  [27]. In 1908 Charles 
Mantoux introduced tuberculin injections into a skin. 
Florence Seibert developed purified protein derivative 
(PPD). With an availability of well-standardized PPD, 
careful studies of tuberculin reaction sizes became pos-
sible and such studies led to further knowledge of my-
cobacterial infections. In 1952 Carroll Palmer and Leroy 
Batt published a large-scale research work providing as-
sessment of tuberculin reaction in TB patients. Reaction 
of the five tuberculin units (PPD-S) had an average of 17 
mm [28]. After three years, the World Health Organiza-
tion (WHO) published a report describing reaction of the 
healthy school children to tuberculin, which was similar 
to that of patients with tuberculosis - they were diag-
nosed with latent tuberculosis [29]. 
In Lithuania 1924, 59 tuberculin tests were performed 
in Kaunas City Municipality Tuberculosis Dispensary. 
In 1934 totally 483 tests were conducted. In 1925 the 
Pirquet tests were performed in Kaunas city Vilijampole 
district schools, which showed that about 80 percent of 
children aged 7-14 were infected with tuberculosis [22]. 
Tuberculin testing with Dermatubin by rubbing it into 
a skin was also conducted [30]. In 1938 it was decided 
to oblige doctors to perform tuberculin testing in all 
students by Dermatubin, Pirquet or Manthoux meth-
ods [31].
Sanatorium for tuberculosis treatment
In 1859 Herman Brehmer opened the first sanatorium 
for tuberculosis in Germany. The rest and nutrition regi-
men was observed in the sanatorium. Soon sanatoriums 
for tuberculosis treatment were opened in other coun-
tries [32].
Effects of the sanatorium care to the disease outcome 
were indistinct. In 1923 G. Lissant Cox published his 5 
years lasting research, the aim of which was to compare 
the mortality of patients treated at home and in sana-
torium. The research showed that case fatality rate was 
higher in those (about 20 per cent.), who were treated at 
home [33]. 
In Lithuania sanatorium patients received not only a 
high-quality food, procedures including sunbathing 
(Fig. 2), ultraviolet radiation, pneumothorax (Fig. 3), 
irradiation with quartz lamps (Fig. 4), but toracoplastic 
were also applied. 
First child (12 years) in the pictures is also treated for 
neck tuberculosis. Treatment procedure with Rollier ma-
chine is carried out by stretching his head [31].
Dr. Dakinevicius performs pneumothorax procedure in 
the Mazeikiai Department Dispensary [34].
Room at the Panemunes sanatorium, Lithuania [18]. 
Fig. 2. Sunbathing procedure in the Dr. K. Grinius sanatorium, 
Lithuania, 1938.
Fig. 3. Pneumothorax procedure. Mazeikiai Department Dispen-
sary, Lithuania, 1936.
Fig. 4. Irradiation with quartz lamps, Lithuania.
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In 1696 Giorgio Baglivi described improvement in con-
dition of tuberculosis patient after experiencing trau-
matic pneumothorax (person was injured with a sword). 
The first therapeutic pneumothorax procedure was per-
formed in London by F.H. Ramadge in 1834. In 1939 Oli 
Hjaltested and Kjeld To described outcomes of this pro-
cedure in 191 patients. Before the procedure, all patients 
were MT-positive, after procedure 65 died, 11 remained 
MT-positive, 8 - were treated further and 107 patients 
discontinued treatment because of an achieved desired 
result [35].
In 1891 the first sanatorium-summerhouse was built in 
Lithuania by military doctor Paskevicius near the Kazlu 
Ruda railway station. Sanatorium was assigned to indi-
viduals with “weak” lungs [22]. In 1925 the Department 
of Health set up sanatorium also in Jurbarkas, which 
had 50 beds  [21]. In 1927 sanatorium was opened in 
Varena  [34]. Similarly, the Latvian SCT maintained 3 
children’s sanatoriums (Ogruos, Bikernuos and Roden-
poize) with 265 beds. Also, the Latvian Red Cross (RC) 
had 5 sanatoriums, the Patient Fund - 6 sanatoriums (320 
beds). There were several private and one public sanato-
riums. Latvia had 1.100 beds in total for patients with 
tuberculosis. At the same time, Denmark allocated 3.5 
thousand beds for patients [24]. In the special inter-war 
tuberculosis publication it was noted that the sanatorium 
had modern equipment, central heating, sewer, electric 
light and 17-staff personnel. Since the start of sanato-
rium operation until 1934 322 Lithuanians, 140 Jews, 14 
German, 12 Russian and 8 Poles were treated. In 1938 
a school was established at the sanatorium [22, 31]. To 
combat tuberculosis, SCT opened a new modern sanato-
rium in Alytus in 1939. Construction of the Sanatorium 
new building costed over 170 thousand Litas (about 50 
thousand Euro). It was planned to treat 50 patients in 
there. One of the main objectives of SCT was to isolate 
incurable patients. Following the Norwegian example, 
SCT planned to establish colonies for incurable patients. 
Isolation was one of the key objectives of SCT. Colonies 
should be established in Alytus, Utena with capacities 
of each for 15 patients [21]. In 1932 a four-story brick 
Lithuanian RC sanatorium was established in Kaunas 
with designated 1.75 hectare plot of land. This sanato-
rium was owned by the Lithuanian RC, founded in 1919. 
In 1933 a private sanatorium for children owned by Prof. 
Dr. V. Tumeniene was established in Panemune [36].
In 1936 a possibility to employ the patients in the newly 
opened sanatoriums was discussed to reduce the pa-
tients’ maintenance costs by recruiting patients at the 
sanatorium. A similar example was applied in Switzer-
land [34].
Sanatorium patients were treated “conservatively” and 
“actively”. Conservative treatment was applied accord-
ing to the Brehmer Dettweiler’s Hygiene - Dietics sys-
tem, providing the patients with the peace of mind and 
good quality food, fresh air and sunlight [22]. Patients 
were recommended to consume 2.5-3 thousand calories. 
The treatment included respiratory gymnastic, treatment 
with sunlight was administered to persons with larynx 
tuberculosis. Sunbath positive effect on people with tu-
berculosis was also widely discussed. Following the Ber-
lin’s good practices, it was proposed to arrange beaches 
at rivers in Kaunas, Panevezys and other cities [24].
Pneumothorax, neurosurgeries, oleothorax, thoraco-
caustic, thoracoplastic procedures, filling of lung cavi-
ties, treatment with collapse have been applied in the 
sanatoriums. Heliotherapy, extension were used for bone 
and joint tuberculosis, X-ray therapy for glandular tu-
berculosis [22, 24]. The intercostal nerve alcoholisation 
treatment was also applied: alcohol used to be injected 
into nerves triggering the muscle paralysis [30].
In 1927 treatment of tuberculosis with gold preparation 
Sanokrisin were discussed. The Health Department put 
a ban on import of this preparation. In 1934 the treat-
ment with gold preparations (Sanokrisin, Triphala) was 
applied in Panemune sanatorium [22, 24].
Hospitals for tuberculosis treatment
Vilnius Hospital of Infectious Diseases was founded in 
1905, when two brick buildings were erected for Chil-
dren Infectious Diseases Hospital in Zverynas district 
of Vilnius. In 1911, several one store wooden buildings 
were additionally erected for the treatment of adult pa-
tients next to two brick buildings for the children. Pa-
tients with typhoid fever, typhus exanthematicus, epi-
demic relapsing fever, dysentery, cholera, meningitis, 
tuberculosis and trachoma were treated in this Hospital. 
The Hospital had 150 beds, 6 wards, 5 physicians and 
one microbiologist [37].
The first tuberculosis hospital was opened in Lithuania 
in 1923 as division of the Kaunas State Hospital. In 1926 
the hospital with functionary surgery clinic was avail-
able to tuberculosis patients, patients with bone tuber-
culosis were referred to this Hospital. The Polyclinic-
Ambulance was open every day except Sundays and 
holidays. X-ray costed 20 Litas (about 6 Euro), sputum 
examination and testing - 3 Litas (about 0.9 Euro). Poor 
people with permission from the City and District Board 
were treated for free. The National Institute of Hygiene 
was also accessible where research was conducted. 
Pulmonary patients were treated in the Kaunas Health 
Centre (Dispensary) where pneumothorax and sputum 
examination were available. It was the first health care 
centre in Lithuania for patients with tuberculosis. The 
Lung Hospital in Jurbarkas was considered one of the 
best hospitals in Lithuania. The Hospital maintained 50 
beds, so patients had to wait in long queues. Further 80 
beds were available in Varena [21].
The patients applying to the medical institutions usually 
suffered from neglected tuberculosis. People from rural 
areas often discontinued the treatment due to a lack of 
money  [24]. The patients had to pay for the medicine 
themselves; some departments had agreements with 
pharmacies to sell medicines at lower prices. Medica-
tion for the poorest used to be reimbursed by the munici-
pality. The patients used to receive travel, monetary and 
food allowances [22].
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Tuberculosis - public health problem
In 1881 doctor Herman Biggs pinpointed tuberculo-
sis as a public health problem. In 1889 he accentuated 
importance of tuberculosis case reporting. In 1894 H. 
Biggs was able to convince the New York City Board 
of Health that tuberculosis must be a notifiable dis-
ease. These instructions were not required until 1897. 
Health care specialists opposed to these directives up 
to 1900 [32, 38].
Tuberculosis was attributed to the public health prob-
lems also in Lithuania. Dr. A. Domasevicius in his paper 
Tuberculosis and a quest of other new ways to defeat it 
in 1934 mentioned that tuberculosis was not a disease of 
an individual, not a family disease; tuberculosis is the 
disease of the general population [22].
At the beginning of the 20th century, no broader 
measures to combat the disease were taken in the 
Russian Empire. Medical Service of the Russian 
Ministry of Internal Affairs summoned Commission 
for Combating Tuberculosis, which issued a circu-
lar on measures to combat tuberculosis in 1908 and 
Circular on the cards for Tuberculous disease regis-
tration in 1909 [22]. A reporting of the tuberculosis 
cases started in Lithuania in 1926 [21]. A registration 
of tuberculosis cases and deaths was not mandatory. 
A consideration was given to prepare and publish a 
law that empowered to notify any case of open tu-
berculosis [24]. In the work plan/estimate for 1926, 
case tracing was foreseen allowing a free delivery of 
phlegm to the laboratory, this model was applied at 
the time in America. In 1933 The law for combating 
contagious diseases (CD) was passed, which enabled 
reporting of tuberculosis cases to the municipality, 
but its execution wasn’t controlled [21].
Bacillus Calmette-Guérin (BCG) vaccine 
Doctor bacteriologist Albert Calmette and his colleague 
veterinarian Camille Guerin at the French Pasteur Insti-
tute attenuated M. bovis in 1921. BCG vaccine was ready 
for testing. A newborn, whose mother died of pulmonary 
tuberculosis, was first vaccinated with this vaccine. The 
child did not develop tuberculosis. Over the next seven 
years, more than 100 thousand children were vaccinated 
with this vaccine. The vaccine was readily available in 
Europe [39, 40].
In 1934 the launch of BCG vaccination was discussed 
in Lithuania, but this was not possible due to technical 
problems. One of the mentioned measures was for the 
National Institute of Hygiene or the Veterinary Bacteri-
ology Institute to obtain original BCG culture from the 
Paris Pasteur Institute, to prepare it and supply to the 
hospitals and shelters through dispensaries as a preven-
tive measure. In 1935 Kaunas was the first to start the 
BCG vaccination. In November, three children whose 
mothers had tuberculosis were vaccinated at the time 
of delivery. The vaccine used to be obtained from the 
Riga University Serological Institute [34]. It was recom-
mended to vaccinate the infants within ten days of their 
birth [30]. Vaccination was widely used, so in 1939 the 
Department of Health had planned to oblige the Dispen-
sary Heads to perform this [22].
In 1947 the first WHO Expert Committee meeting took 
place, it was decided to assist the governments in devel-
oping effective TB control programmes based on BCG 
vaccination and case management. Since then, the case 
management has remained a major tuberculosis manage-
ment strategy [41]. In 1948 United Nations International 
Children’s Emergency Fund and the Danish RC funded 
campaign of tuberculin testing and BCG vaccination 
of those tested negative was carried out. The campaign 
was launched in Poland and quickly spread to other Eu-
ropean countries. Within three years, nearly 30 million 
people were tested with tuberculin test, and nearly 14 
million were vaccinated. This campaign was the first 
programme conducted by the WHO  [42, 43]. In 1974 
the WHO Tuberculosis Committee published the ninth 
report and tuberculosis control guidelines for the next 
two decades. The guidelines emphasized significance of 
the sputum microscopy and outpatient treatment calling 
to reach 70-80 percent vaccination coverage in the age 
group of less than 15-20 years [44].
In 2016 Among the Baltic States highest vaccination 
coverage was in Lithuania (98%), lowest in Estonia 
(95%) [45].
Directly observed treatment short course 
With the advent of effective chemotherapy in the mid-
1950s, sanatoriums began to become superfluous. By 
the mid-1960s most were closed. Hospital care was no 
longer required to provide effective treatment. A study 
in Madras, in which patients with tuberculosis were ran-
domly assigned to either sanatorium or home treatment, 
showed no difference in either clinical outcomes or in-
fection in the household contacts. Sanatoriums became 
obsolete [46, 47]. Along with the chemotherapy, a long-
term patient hospitalization became a key principle of 
tuberculosis control. The objective was to introduce the 
directly observed therapy (DOT). The first similar clinic 
was opened in 1950. Attempts to switch to DOT were 
made not only in Madras, Hong Kong [48, 49] but also 
in London  [50, 51]. Selective DOT programmes were 
integrated in America in 1960. They were applied only 
in unreliable patients [52, 53]. DOTS was an important 
development in global tuberculosis policy. Increas-
ingly, poor countries began implementing the DOTS 
approach; many lives were saved and many new cases 
averted. However, for children with tuberculosis, peo-
ple with both tuberculosis and advanced disease from 
the human immunodeficiency virus (HIV), and the in-
creasing proportion of patients infected with strains of 
tuberculosis that were already drug-resistant, the DOTS 
strategy provided limited options for prompt diagnosis 
and cure [54].
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Lithuania introduced DOTS in 1999 and from 2007 it 
has been working in accordance with the requirements 
of this strategy [55].
Nowadays TB is still a major public health problem, for 
this reason a combined strategy, based on improving 
drug treatment, diagnostic instruments, and prevention 
strategy, is necessary in order to eradicate M. Tuberculo-
sis by the year 2050, as committed by the WHO [56, 57]. 
Despite considerable efforts (Fig. 5) Lithuania is facing 
a number of operational problems in a fight against TB, 
especially in TB case management. The mechanisms for 
effective follow-up of patients to prevent them from de-
faulting are underdeveloped [58].
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